SMT201600134B - Derivato biciclico fuso di 2, 4-diamminopirimidina come un inibitore doppio di alk e fak. - Google Patents

Derivato biciclico fuso di 2, 4-diamminopirimidina come un inibitore doppio di alk e fak.

Info

Publication number
SMT201600134B
SMT201600134B SM201600134T SM201600134T SMT201600134B SM T201600134 B SMT201600134 B SM T201600134B SM 201600134 T SM201600134 T SM 201600134T SM 201600134 T SM201600134 T SM 201600134T SM T201600134 B SMT201600134 B SM T201600134B
Authority
SM
San Marino
Prior art keywords
diamminopyrimidine
molted
fak
alk
double inhibitor
Prior art date
Application number
SM201600134T
Other languages
English (en)
Italian (it)
Inventor
Martin J Jacobs
Gregory R Ott
Laurent Courvoisier
Shawn P Allwein
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47892060&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT201600134(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of SMT201600134B publication Critical patent/SMT201600134B/it

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
SM201600134T 2012-03-06 2016-05-10 Derivato biciclico fuso di 2, 4-diamminopirimidina come un inibitore doppio di alk e fak. SMT201600134B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261607305P 2012-03-06 2012-03-06
PCT/US2013/029304 WO2013134353A1 (en) 2012-03-06 2013-03-06 Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor

Publications (1)

Publication Number Publication Date
SMT201600134B true SMT201600134B (it) 2016-07-01

Family

ID=47892060

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201600134T SMT201600134B (it) 2012-03-06 2016-05-10 Derivato biciclico fuso di 2, 4-diamminopirimidina come un inibitore doppio di alk e fak.

Country Status (28)

Country Link
US (5) US9132128B2 (enExample)
EP (2) EP2822939B1 (enExample)
JP (2) JP6016953B2 (enExample)
KR (1) KR102068374B1 (enExample)
CN (2) CN106166155B (enExample)
AU (1) AU2013229995B2 (enExample)
CA (1) CA2865420C (enExample)
CL (1) CL2014002353A1 (enExample)
CY (1) CY1117565T1 (enExample)
DK (1) DK2822939T3 (enExample)
EA (2) EA033124B1 (enExample)
ES (2) ES2681487T3 (enExample)
HR (1) HRP20160387T1 (enExample)
HU (1) HUE027976T2 (enExample)
IL (2) IL234239A (enExample)
ME (1) ME02460B (enExample)
MX (2) MX347772B (enExample)
MY (1) MY177290A (enExample)
NZ (1) NZ630251A (enExample)
PH (1) PH12014501979B1 (enExample)
PL (1) PL2822939T3 (enExample)
RS (1) RS54689B1 (enExample)
SG (2) SG11201405371PA (enExample)
SI (1) SI2822939T1 (enExample)
SM (1) SMT201600134B (enExample)
UA (1) UA115052C2 (enExample)
WO (1) WO2013134353A1 (enExample)
ZA (1) ZA201406147B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2865420C (en) * 2012-03-06 2020-06-02 Cephalon, Inc. Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor
EP3125920B1 (en) 2014-04-04 2020-12-23 Del Mar Pharmaceuticals Dianhydrogalactitol, diacetyldianhydrogalactitol or dibromodulcitol to treat non-small-cell carcinoma of the lung and ovarian cancer
JP6849594B2 (ja) * 2014-12-23 2021-03-24 セファロン、インク. 縮合二環式2,4−ジアミノピリミジン誘導体を調整する方法
AU2019319109A1 (en) 2018-08-07 2021-02-25 In3Bio Ltd. Methods and compositions for inhibition of EGF/EGFR pathway in cobination with anaplastic lymphoma kinase inhibitors
WO2024178339A2 (en) * 2023-02-23 2024-08-29 The Regents Of The University Of Michigan Methods for treating neuroblastoma with a dual anaplastic lymphoma kinase and focal adhesion kinase inhibitor
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004259012C1 (en) 2003-07-23 2012-08-02 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
RU2395500C2 (ru) 2003-08-15 2010-07-27 Новартис Аг 2,4-пиримидиндиамины, применяемые в лечении неопластических болезней, воспалительных и иммунных расстройств
DK1713806T3 (da) * 2004-02-14 2013-08-05 Irm Llc Forbindelser og sammensætninger som proteinkinaseinhibitorer
WO2005097765A1 (en) 2004-03-31 2005-10-20 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
ES2622493T3 (es) * 2006-02-24 2017-07-06 Rigel Pharmaceuticals, Inc. Composiciones y métodos para la inhibición de la ruta de JAK
ES2633318T3 (es) * 2006-10-23 2017-09-20 Cephalon, Inc. Derivados bicíclicos fusionados de 2,4-diaminopirimidina como inhibidores de ALK y c-Met
EP3012249A1 (en) * 2006-12-08 2016-04-27 Novartis AG Compounds and composition as protein kinase inhibitors
ES2593486T3 (es) * 2007-04-18 2016-12-09 Pfizer Products Inc. Derivados de sulfonil amida para el tratamiento del crecimiento celular anómalo
WO2010143664A1 (ja) * 2009-06-10 2010-12-16 中外製薬株式会社 4環性化合物
CA2865420C (en) * 2012-03-06 2020-06-02 Cephalon, Inc. Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor
KR101446742B1 (ko) * 2012-08-10 2014-10-01 한국화학연구원 N2,n4-비스(4-(피페라진-1-일)페닐)피리미딘-2,4-디아민 유도체 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
JP6849594B2 (ja) * 2014-12-23 2021-03-24 セファロン、インク. 縮合二環式2,4−ジアミノピリミジン誘導体を調整する方法

Also Published As

Publication number Publication date
EP2822939B1 (en) 2016-02-17
SI2822939T1 (sl) 2016-04-29
IL252364B (en) 2018-03-29
HUE027976T2 (en) 2016-11-28
CA2865420C (en) 2020-06-02
JP2015509540A (ja) 2015-03-30
CN104159894B (zh) 2016-09-07
MX2014010613A (es) 2014-09-18
KR102068374B1 (ko) 2020-01-20
MX347772B (es) 2017-05-12
MX372740B (es) 2020-05-04
CL2014002353A1 (es) 2015-01-09
EA025859B1 (ru) 2017-02-28
US20150011561A1 (en) 2015-01-08
DK2822939T3 (en) 2016-03-14
MY177290A (en) 2020-09-10
ES2681487T3 (es) 2018-09-13
EP3056494A1 (en) 2016-08-17
EA201691574A1 (ru) 2017-03-31
IL234239A (en) 2017-06-29
AU2013229995A1 (en) 2014-09-25
US20170173017A1 (en) 2017-06-22
NZ630251A (en) 2016-02-26
EP3056494B1 (en) 2018-05-02
JP6016953B2 (ja) 2016-10-26
CN104159894A (zh) 2014-11-19
SG10201507865QA (en) 2015-10-29
ES2570976T3 (es) 2016-05-23
CN106166155B (zh) 2019-01-18
HRP20160387T1 (hr) 2016-05-20
RS54689B1 (sr) 2016-08-31
US20190328735A1 (en) 2019-10-31
IL252364A0 (en) 2017-07-31
WO2013134353A8 (en) 2014-06-19
ZA201406147B (en) 2015-12-23
WO2013134353A1 (en) 2013-09-12
AU2013229995B2 (en) 2017-04-13
PH12014501979A1 (en) 2014-11-24
US10111872B2 (en) 2018-10-30
PH12014501979B1 (en) 2014-11-24
EA033124B1 (ru) 2019-08-30
HK1205119A1 (zh) 2015-12-11
US20160243119A1 (en) 2016-08-25
PL2822939T3 (pl) 2016-08-31
US10632119B2 (en) 2020-04-28
EA201491641A1 (ru) 2015-04-30
CN106166155A (zh) 2016-11-30
US9339502B2 (en) 2016-05-17
US9623026B2 (en) 2017-04-18
SG11201405371PA (en) 2014-09-26
UA115052C2 (uk) 2017-09-11
JP2017039741A (ja) 2017-02-23
CA2865420A1 (en) 2013-09-12
EP2822939A1 (en) 2015-01-14
ME02460B (me) 2017-02-20
HK1226300A1 (zh) 2017-09-29
KR20140138247A (ko) 2014-12-03
US9132128B2 (en) 2015-09-15
US20150374693A1 (en) 2015-12-31
CY1117565T1 (el) 2017-04-26

Similar Documents

Publication Publication Date Title
SMT201600134B (it) Derivato biciclico fuso di 2, 4-diamminopirimidina come un inibitore doppio di alk e fak.
SMT201700052B (it) 2-(azaindol-2-il)benzimidazoli come inibitori di pad4
DK3071203T3 (da) Tetrahydroquinolinsammensætninger som bet-bromdomæne-inhibitorer
HUE036259T2 (hu) Inhibitor vegyületek
SI3715345T1 (sl) Priprava zaviralca lfa-1
DK3181567T5 (da) Pyrazolopyrimidinforbindelser som kinasehæmmere
DK2920149T3 (da) 3-aminocycloalkyl-forbindelser som ror-gamma-t-inhibitorer og anvendelser deraf
LT3702351T (lt) Kompozicijos, apimančios mek inhibitorių
SMT201600114B (it) Inibitori di beta-secretasi
WO2014047502A3 (en) Anhydrous compositions having microcapsules and non-volatile oils
DK2804858T3 (da) Metalloenzym-inhibitorforbindelser
EP2840076A4 (en) BICYCLIC CONNECTION
EP2863748A4 (en) 1,2,4-triazine-6-CARBOXAMIDKINASEINHIBITOREN
BR112014007719A2 (pt) proteases fúngicas
ME02985B (me) Prolekovi inhibitora amino-hinazolinske kinaze
EP2933248A4 (en) NOVEL RENIN INHIBITOR
SMT201600357B (it) Inibitori di iap
DK2934510T3 (da) Lfa-1-inhibitorformuleringer
EP3082822A4 (en) Hiv protease inhibitors
EP3083609A4 (en) Hiv protease inhibitors
ITTO20110857A1 (it) Procedimento per la produzione di cicloesanonossina.
EP2875885A4 (en) Novel drill chuck
FR2959588B1 (fr) Condensateur auto-protege.
FR2991112B1 (fr) Laser semiconducteur optimise
DE102010048360A8 (de) Laserzünder